Metabolon

Metabolon Partners with the University of Oxford Parkinson's Disease Centre

Retrieved on: 
Tuesday, August 23, 2022
ISO, Metabolomics, University, CEO, Technology, RBD, Research, Ghana Infectious Disease Centre, Solution, Rapid eye movement sleep behavior disorder, Disease, Lipidomics, Precision medicine, CSF, LinkedIn, Parkinson's disease, Diet, Multimedia, Health, Biology, Publication, Population, Twitter, Biomarker, Genetic variation, REM, Risk, Cerebrospinal fluid, University of Oxford, Patient, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Aug. 23, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced it is partnering with the University of Oxford Parkinson's Disease Centre to identify metabolomic biomarkers related to Parkinson's disease progression and prediction and to detect new therapeutic targets.

Key Points: 
  • The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford.
  • Through this collaboration, Metabolon will perform global metabolomics on longitudinal serum and cerebrospinal fluid (CSF) samples collected by OPDC.
  • This will enable Metabolon and Oxford to gain insights into the metabolomic changes occurring during Parkinson's disease progression over many years in this deeply phenotyped cohort.
  • "We are thrilled to partner with the Oxford Parkinson's Disease Centre to support their mission to improve research and understanding of the biology of early Parkinson's," said Rohan Hastie, Ph.D., President and CEO of Metabolon.

Metabolon Partners with the University of Oxford Parkinson's Disease Centre

Retrieved on: 
Tuesday, August 23, 2022
ISO, Metabolomics, University, CEO, Technology, RBD, Research, Ghana Infectious Disease Centre, Solution, Rapid eye movement sleep behavior disorder, Disease, Lipidomics, Precision medicine, CSF, LinkedIn, Parkinson's disease, Diet, Health, Biology, Publication, Population, Twitter, Biomarker, Genetic variation, REM, Risk, Cerebrospinal fluid, University of Oxford, Patient, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Aug. 23, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced it is partnering with the University of Oxford Parkinson's Disease Centre to identify metabolomic biomarkers related to Parkinson's disease progression and prediction and to detect new therapeutic targets.

Key Points: 
  • The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford.
  • Through this collaboration, Metabolon will perform global metabolomics on longitudinal serum and cerebrospinal fluid (CSF) samples collected by OPDC.
  • This will enable Metabolon and Oxford to gain insights into the metabolomic changes occurring during Parkinson's disease progression over many years in this deeply phenotyped cohort.
  • "We are thrilled to partner with the Oxford Parkinson's Disease Centre to support their mission to improve research and understanding of the biology of early Parkinson's," said Rohan Hastie, Ph.D., President and CEO of Metabolon.

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

Retrieved on: 
Tuesday, August 9, 2022
Multimedia, Biomarker, Inflammatory arthritis, Precision medicine, Inflammatory bowel disease, Diet, CEO, Technology, Non-alcoholic fatty liver disease, Mayo Clinic, Genetic variation, Research, Twitter, Pancreatic cancer, NAFLD, Alzheimer's disease, Breast cancer, Lipidomics, Metabolomics, Publication, ISO, Solution, LinkedIn, Health, Medical imaging, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Aug. 9, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests. Metabolon will analyze Mayo Clinic patient clinical samples across multiple cohorts to look for disease biomarkers. New diagnostic tests for Mayo Clinic to use in its nationwide Mayo Clinic Laboratories will be designed using these biomarkers.

Key Points: 
  • MORRISVILLE, N.C., Aug. 9, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests.
  • Metabolon will analyze Mayo Clinic patient clinical samples across multiple cohorts to look for disease biomarkers.
  • New diagnostic tests for Mayo Clinic to use in its nationwide Mayo Clinic Laboratories will be designed using these biomarkers.
  • Metabolon and Mayo Clinic will initially focus their investigation on metabolite biomarkers indicating inflammatory bowel disease and non-alcoholic fatty liver disease (NAFLD).

Metabolon Awarded ISO 9001:2015 Recertification

Retrieved on: 
Tuesday, August 2, 2022
Knowledge, ISO, Metabolomics, Twitter, CEO, International Organization for Standardization, Culture, Research, Biomarker, Solution, Lipidomics, Health, Diet, Multimedia, Organization, Certification, Leadership, International Organization (journal), QMS, Drug development, Technology, Publication, Genetic variation, ISO 9001:2015, LinkedIn, Precision medicine, Audit, Medical device, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced it has obtained ISO 9001:2015 recertification from SGS North America Inc. as of July 15, 2022. Having received initial certification in 2019, this recertification reflects Metabolon's dedication to delivering the highest standard of quality assurance throughout all of its processes, including research and development, product and service testing, delivery, support, and customer service.

Key Points: 
  • ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards
    MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced it has obtained ISO 9001:2015 recertification from SGS North America Inc. as of July 15, 2022.
  • "This recertification demonstrates our continued commitment to delivering high-quality, high-value products and services to our customers.
  • "Metabolon has demonstrated their commitment to quality and focus on meeting customer needs by successfully completing the rigorous ISO 9001:2015 audit process and achieving recertification," said Tomas Miko, Director of Sales, SGS North America, Knowledge Division.
  • Over 20 years, 10,000+ projects, 2,800+ publications, and ISO 9001:2015 andCLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.

Metabolon Awarded ISO 9001:2015 Recertification

Retrieved on: 
Tuesday, August 2, 2022
Knowledge, ISO, Metabolomics, Twitter, CEO, International Organization for Standardization, Culture, Research, Biomarker, Solution, Lipidomics, Health, Diet, Organization, Certification, Leadership, International Organization (journal), QMS, Drug development, Technology, Publication, Genetic variation, ISO 9001:2015, LinkedIn, Precision medicine, Audit, Medical device, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced it has obtained ISO 9001:2015 recertification from SGS North America Inc. as of July 15, 2022. Having received initial certification in 2019, this recertification reflects Metabolon's dedication to delivering the highest standard of quality assurance throughout all of its processes, including research and development, product and service testing, delivery, support, and customer service.

Key Points: 
  • ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards
    MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced it has obtained ISO 9001:2015 recertification from SGS North America Inc. as of July 15, 2022.
  • "This recertification demonstrates our continued commitment to delivering high-quality, high-value products and services to our customers.
  • "Metabolon has demonstrated their commitment to quality and focus on meeting customer needs by successfully completing the rigorous ISO 9001:2015 audit process and achieving recertification," said Tomas Miko, Director of Sales, SGS North America, Knowledge Division.
  • Over 20 years, 10,000+ projects, 2,800+ publications, and ISO 9001:2015 andCLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.

Metabolon Appoints Tom Houseman as Vice President of Operations

Retrieved on: 
Monday, July 25, 2022
ISO, Metabolomics, Twitter, CEO, Environmental studies, NextGen Healthcare, Research, Biomarker, Houseman, Solution, Compliance, Lipidomics, Health, Diet, Multimedia, Drug development, Publication, Technology, Genetic variation, Patient, LinkedIn, Precision medicine, Efficiency, East Stroudsburg University of Pennsylvania, Growth, BioMérieux, Management, Fine chemical, Pharmaceutical industry, Metabolon, Biology, Hospira, Science, Operation

MORRISVILLE, N.C., July 25, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced that Tom Houseman has been appointed Vice President of Operations. Joining the company's leadership team, Houseman will be instrumental in accelerating and enabling process efficiency and capability across Metabolon testing and operations, as well as Metabolon facilities.

Key Points: 
  • An accomplished leader in laboratory innovations and diagnostics, Houseman will enable process efficiency and capability across Metabolon testing and operations
    MORRISVILLE, N.C., July 25, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced that Tom Houseman has been appointed Vice President of Operations.
  • Joining the company's leadership team, Houseman will be instrumental in accelerating and enabling process efficiency and capability across Metabolon testing and operations, as well as Metabolon facilities.
  • Previously, Houseman served as Vice President of Operations at bioMerieux, Inc, where he led all aspects of manufacturing and supply for bioMerieux's 500-person Durham production site.
  • "We are delighted to welcome Tom to the Metabolon team," said Rohan (Ro) Hastie, President & CEO of Metabolon.

Metabolon Partnership with University of Maryland School of Medicine Amish Research Program Leverages Metabolomics to Identify Novel Biomarkers

Retrieved on: 
Tuesday, June 21, 2022
Nutrition, CSO, Solution, Metabolomics, Population, ISO, Drug development, Maryland School, University of Maryland School of Medicine, Environment, Genetics, Publication, Technology, Gene, CEO, Holmes Old Order Amish affiliation, Precision medicine, OOA, Research, LinkedIn, WES, Disease, Diet, University, Genetic variation, Health, Decision-making, Diabetes, Biomarker, HIV disease progression rates, Partnership, Blood, Twitter, Patient, Multimedia, Lipidomics, Division, Pharmaceutical industry, Medicine, Metabolon, Endocrinology

MORRISVILLE, N.C., June 21, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, is partnering with the University of Maryland School of Medicine (UMSOM) to bring the latest technological advances to the School's Amish Research Program. Metabolon's researchers will leverage metabolomics information to explore the intersection of genes and environment to understand human health and disease through this data-sharing initiative. Creating biochemical profiles of this genetically unique population will help physician-scientists more deeply understand the basics of incidental disease.

Key Points: 
  • MORRISVILLE, N.C., June 21, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, is partnering with the University of Maryland School of Medicine (UMSOM) to bring the latest technological advances to theSchool's Amish Research Program.
  • Population health researchers are increasingly turning to multi-omics to inform on the state of health and disease progression among populations.
  • The Amish community is ideal for study due to its common lineage and homogeneous lifestyle.
  • Pharmaceutical researchers have been involved with the UMSOM Amish cohort since 2015, performing whole-exome sequencing (WES) on samples.

Metabolon Expands Data Access Strategy to Include TwinsUK Registry

Retrieved on: 
Tuesday, June 7, 2022
Imperial College London, TwinsUK, Biomarker, Precision medicine, Adult, King's College London, Research, Urine, Human, Kings, LinkedIn, Ageing, Metabolomics, London, CEO, Partnership, King, Disease, Environment, REF, Blood, Solution, Gene, Cardiovascular disease, Genetic variation, Student, Genetics, ISO, Publication, Lipidomics, Metabolic syndrome, Technology, Health, College and university rankings, COVID-19, Phenotype, Data, Twitter, Diet, CSO, Drug development, University, Pharmaceutical industry, Dietary supplement, Metabolon

MORRISVILLE, N.C., June 7, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, announces a partnership with King's College London to perform metabolomics analysis on TwinsUK registry samples as part of Metabolon's data access strategy. The size and clinical detail of the TwinsUK cohort will allow Metabolon to investigate a broad number of diseases for new relevant biomarkers and support novel therapeutic development for improved patient outcomes.

Key Points: 
  • The TwinsUK registry is one of the most significant adult twins biospecimens and clinical collections worldwide.
  • Through this collaboration, Metabolon will analyze data from global metabolomics and targeted short-chain fatty acid assays on fecal, blood, urine, and saliva samples collected by TwinsUK.
  • This will enable Metabolon and TwinsUK to gain insights into the interplay between the gut microbial community and human health.
  • Additionally, the partners will examine clinical data and compare previous metabolomics research studies with the TwinsUK dataset.

Metabolon Appoints New Vice President of Global Marketing, Supporting Commercial Product Expansion

Retrieved on: 
Thursday, May 19, 2022
MBA, SCU Leavey School of Business, Paul H. Nitze School of Advanced International Studies, International relations, Public relations, Multimedia, Goal, Uncertainty, Science, Solution, Health, Santa Clara University, Iverson, Genetics, Metabolomics, Research, Lipidomics, Global marketing, Biotechnology, Diet, Technology, Biomarker, Brigham Young University, Drug development, Danaher, LinkedIn, Precision medicine, Cisco Systems, Twitter, Genetic variation, Sophia Genetics, ISO, Business, CEO, Publication, Management, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., May 19, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, has appointed Sean Iverson as Vice President of Global Marketing.

Key Points: 
  • MORRISVILLE, N.C., May 19, 2022 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, has appointed Sean Iverson as Vice President of Global Marketing.
  • "As the market leader in metabolomics, Metabolon has the opportunity to drive innovations supporting the full scope of life sciences," said Iverson.
  • Iverson has driven success in his prior roles, emphasizing analytics and data-driven marketing and product efforts with strong commercial results.
  • Most recently, Iverson was Vice President of Global Marketing at Sophia Genetics, leading the company's expansion of commercial and digital marketing, branding, and public relations.

Optinose Announces Appointment of R. John Fletcher to the Board

Retrieved on: 
Tuesday, April 26, 2022
Board, CMU, ENT, National Association, OPTN, MIT, Elective surgery, India–Singapore Comprehensive Economic Cooperation Agreement, Wharton School of the University of Pennsylvania, U.S. Securities and Exchange Commission, Wendell Pritchett, Nose, MBA, Twitter, NASDAQ, Adviser, Securities and Exchange Commission (Nigeria), Aviation, Board of directors, GLOBE, National Association of Corporate Directors, Doctor of Philosophy, Sale, Patient, Boston Consulting Group, III, LinkedIn, Metabolon, Thayer School of Engineering, Company, Whitehead Institute, Business, United, Beth Israel Deaconess Medical Center, Cardiology, Marketing, Director, University, MS, Hotel manager, George Washington University, BBA, Ear, Dartmouth College, Pharmaceutical industry, Management, Spectranet, Southern Illinois University

"We are pleased to welcome John to the Optinose Board of Directors," stated Joe Scodari, Chairman of the Optinose Board of Directors.

Key Points: 
  • "We are pleased to welcome John to the Optinose Board of Directors," stated Joe Scodari, Chairman of the Optinose Board of Directors.
  • Optinose values the input of its stockholders and I would like to thank Kingdon Capital and Velan Capital for their nomination of John."
  • Adam Morgan, Managing Member of Velan Capital, said, John is a fantastic addition to the Board who will bring a wealth of experience to help Optinose enhance shareholder value.
  • John works across Fletcher Spaghts practice groups, with a focus on healthcare.